Focusing on recent developments in PET agents and technologies that are changing the practice of nuclear medicine and diagnostic imaging, this Online Course emphasizes key indications, common scenarios, and clinical applications.

Learning Outcomes and Lectures
After completing this course, the learner should be able to:

- Discuss the role of PET in prostate cancer and neuroendocrine tumor diagnosis and therapy
- Apply the appropriate PET response criteria in to oncologic studies
- Explain the use of PET agents for the assessment of suspected Alzheimer’s disease and other cognitive disorders
- Outline best practices and imaging findings in PET/CT relevant to COVID-19
- Predict the potential clinical applications of FDOPA-PET for cancer and brain imaging

Topics/Speakers : 
Module 1
* Prostate Cancer—S. Galgano
* Neuroendocrine Tumors—A. Goenka
* PET Response Criteria—H. Jacene
Module 2
* Cognitive Disorders—P. Kuo
* PET/MRI—G. Johnson
* FDOPA—J. McConathy
* PET in the COVID-19 Era—E. Rohren

Date of issuance: October 26, 2020
Date of expiration: October 25, 2023